BOSTON and SOUTH SAN FRANCISCO, Calif., March 14, 2023 (GLOBE NEWSWIRE) — Frontier Medicines Company, a precision drugs firm searching for to unlock the proteome to advance breakthrough therapies towards in any other case undruggable disease-causing targets, at the moment introduced upcoming displays that includes preclinical knowledge on its novel twin KRASG12C inhibitor FMC-376 and advances from the Frontier™ Platform. These knowledge can be introduced on the upcoming American Affiliation for Most cancers Analysis (AACR) Annual Assembly going down April 14th-19th in Orlando, Florida.
Preclinical knowledge unveiling FMC-376’s discovery and distinctive mode of motion can be featured in an oral mini-symposium on Small Molecule Therapeutic Brokers on April 16th, adopted by a presentation on the Frontier Platform in an April 18th poster session.
“A long time after the human genome mission, there stays a excessive unmet want for efficient and sturdy breakthrough precision medicines focusing on beforehand undruggable targets like KRAS,” stated Chris Varma, Ph.D., Frontier’s co-founder, chairman, and CEO. “We’re excited to share knowledge exhibiting how our novel twin inhibitor FMC-376 is designed to quickly and straight shut down each lively and inactive KRASG12C. These findings additional validate the power of the Frontier™ Platform to unlock the proteome for the invention of remedies that may probably create a greater future for individuals with most cancers and different severe circumstances.”
Particulars on the displays are as follows:
Presentation Info
|
Title: |
Discovery of FMC-376 a novel orally bioavailable inhibitor of activated KRASG12C |
|
Summary Quantity: |
1142 |
|
Oral Session Title: |
Small Molecule Therapeutic Brokers |
|
Session Date and Time: |
Sunday, April 16, 2023, 3-5 p.m. ET |
|
|
|
|
Title: |
Combining chemoproteomics with machine studying identifies functionally lively covalent fragments for hard-to-drug most cancers drivers |
|
Summary Quantity: |
5333 |
|
Poster Session Title: |
Excessive-throughput Screening, Lead Identification and Optimization, and in Silico Drug Discovery |
|
Session Date and Time: |
Tuesday, April 18, 2023, 1:30-5 p.m. ET |
|
|
|
About Frontier Medicines
Frontier Medicines is a precision drugs firm that has pioneered a robust drug discovery engine, the Frontier™ Platform, designed to generate medicines towards disease-causing proteins beforehand thought of undruggable. The corporate is deploying its applied sciences in chemoproteomics, covalent drug discovery, and machine studying to develop probably groundbreaking medicines for genetically-defined affected person populations, beginning in most cancers. Frontier is advancing a deep pipeline of wholly-owned precision medicines towards a very powerful drivers of most cancers. The corporate’s lead candidate, FMC-376, is a twin inhibitor of lively and inactive KRASG12C. By fully blocking each types of the KRAS mutation, FMC-376 has the potential to beat the non-response and resistance seen with single-acting KRASG12C inhibitors. For extra info on how Frontier is boldly advancing science to defeat illness, go to www.frontiermeds.com and observe us on LinkedIn and Twitter.
Investor and Media Relations Contact:
Victoria Fort
VP, Company Affairs
202.361.0445
[email protected]
